Skip to content
10-Q

Quarterly Report

RECURSION PHARMACEUTICALS, INC. RXRX

0001601830-26-000078

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 529.3M sh
Shares Diluted Q1 2026 · Mar 31, 2025 402.77M sh
Capex Q1 2026 · Mar 31, 2026 $258K
Capex Q1 2026 · Mar 31, 2025 $1.83M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$81.1M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$131.96M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $654.47M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $743.29M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.02B
Stockholders Equity Q1 2026 · Dec 31, 2025 $1.13B
Stockholders Equity Q1 2026 · Mar 31, 2025 $933.95M
Stockholders Equity Q1 2026 · Dec 31, 2024 $1.03B
Current Liabilities Q1 2026 · Mar 31, 2026 $129.7M
Current Liabilities Q1 2026 · Dec 31, 2025 $147.71M
Total Liabilities Q1 2026 · Mar 31, 2026 $314.75M
Total Liabilities Q1 2026 · Dec 31, 2025 $343.27M
Current Assets Q1 2026 · Mar 31, 2026 $709.56M
Current Assets Q1 2026 · Dec 31, 2025 $812.85M
Total Assets Q1 2026 · Mar 31, 2026 $1.34B
Total Assets Q1 2026 · Dec 31, 2025 $1.47B
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.22
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.50
Eps Basic Q1 2026 · Mar 31, 2026 −$0.22
Eps Basic Q1 2026 · Mar 31, 2025 −$0.50
Sga Expense Q1 2026 · Mar 31, 2026 $34.59M
Sga Expense Q1 2026 · Mar 31, 2025 $54.65M
Rd Expense Q1 2026 · Mar 31, 2026 $87.9M
Rd Expense Q1 2026 · Mar 31, 2025 $129.63M
Net Income Q1 2026 · Mar 31, 2026 −$117.5M
Net Income Q1 2026 · Mar 31, 2025 −$202.49M
Operating Income Q1 2026 · Mar 31, 2026 −$128.51M
Operating Income Q1 2026 · Mar 31, 2025 −$191.37M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $12.49M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $21.83M
Revenue Q1 2026 · Mar 31, 2026 $6.47M
Revenue Q1 2026 · Mar 31, 2025 $14.75M